Skip NavigationSkip to Content
Return Return to Search Results

Blocking a4ß7 integrin binding to SIV does not improve virologic control

  1. Author:
    Iwamoto, Nami [ORCID]
    Mason, Rosemarie D [ORCID]
    Song, Kaimei
    Gorman, Jason [ORCID]
    Welles, Hugh C [ORCID]
    Arthos, James [ORCID]
    Cicala, Claudia [ORCID]
    Min, Susie
    King, Hannah A D [ORCID]
    Belli, Aaron J [ORCID]
    Reimann, Keith A [ORCID]
    Foulds, Kathryn E [ORCID]
    Kwong, Peter D [ORCID]
    Lifson,Jeffrey [ORCID]
    Keele,Brandon [ORCID]
    Roederer, Mario [ORCID]

  2. Author Address

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., MassBiologics, University of Massachusetts Medical School, Boston, MA, USA., AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, USA., Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. roederer@nih.gov.,
    1. Year: 2019
    2. Date: Sep 06
  2. Journal: Science (New York, N.Y.)
    1. 365
    2. 6457
    3. Pages: 1033-1036
  4. Type of Article: Article
  5. ISSN: 0036-8075
  1. Abstract:

    A study in nonhuman primates reported that infusions of an antibody against a4ß7 integrin, in combination with antiretroviral therapy, showed consistent, durable control of simian immunodeficiency virus (SIV) in rhesus macaques. The antibody used has pleiotropic effects, so we set out to gain insight into the underlying mechanism by comparing this treatment to treatment with non-neutralizing monoclonal antibodies against the SIV envelope glycoprotein that only block a4ß7 binding to SIV Env but have no other host-directed effects. Similar to the initial study, we used an attenuated strain of SIV containing a stop codon in nef. The study used 30 macaques that all began antiretroviral therapy and then were divided into five groups to receive different antibody treatments. Unlike the published report, we found no sustained virologic control by these treatments in vivo. Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1126/science.aaw7765
  3. PMID: 31488690
  4. View record in Web of Science®
  5. WOS: 000484732700048
  6. PII : 365/6457/1033

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel